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Context: The diagnosis of ovarian hormone-secreting neoplasm in postmenopausal women is currently based on
imaging modalities and selective venography. However, these diagnostic tests are not always accurate. In order
to improve and simplify the diagnosis, we propose a noninvasive hormonal test.
Objective: To report our experience using noninvasive hormonal test for the diagnosis of ovarian hormone
producing tumor in two postmenopausal women.
Design and intervention: Evaluation of androgen and estradiol serum levels following 1. Adrenal hormonal
depression, 2. ovarian hormonal depression and 3. ovarian hormonal stimulation.
Setting: Tertiary care medical center.
Main outcome measures: Changes in androgen and estradiol levels.
Results: In the ﬁrst case, total testosterone, free androgen index and estradiol serum levels decreased following
ovarian depression by GnRH-antagonist (6.9 nmol/L, 67 nmol/L and b70 pmol/L, respectively) and subsequently
increased after ovarian stimulationwith LH (11.5 nmol/L, 117 nmol/L and 176 pmol/L, respectively). Histological
evaluation revealed steroid cell tumor in one ovary. In the second case, estradiol serum levels decreased following
ovarian depression by GnRH-antagonist (73 pmol/L) and subsequently increased following ovarian stimulation
with FSH (118 pmol/L). Histological evaluation revealed granulosa cell tumor in one ovary.
Conclusions: To our knowledge, these are the ﬁrst cases of ovarian hormone-producing tumors in postmenopausal
women diagnosed by noninvasive hormonal test. The proposed test can be considered in postmenopausal
women suspected of having androgen and/or estrogen producing tumors.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Both functional and nonfunctional ovarian neoplasms are known to
produce androgen. Androgen-secreting neoplasms of the ovary are a
rare cause of androgen excess and, account for only 5% of all ovarian
tumors. Most are Sertoli-Leydig cell, lipid cell, theca cell or hilus cell tu-
mors (Lobo, 1991). Granulosa cell tumors of the ovary are rare neoplasm
(Mancaux et al., 2013), estrogen-producing tumors (Geetha and Nair,
2010) and difﬁcult to diagnose (Mancaux et al., 2013).
It is important to identify and remove these tumors. Although clini-
cal history and baseline androgen levels may increase clinical suspicion,per: None
and Gynecology, Meir Medical
. This is an open access article underlocalization of these tumors requires several diagnostic methods, in-
cluding dynamic ovarian and adrenal assessment and diagnostic imag-
ing (Taylor et al., 1986). However, sometimes they are very difﬁcult to
detect, and interpretation of test results can be difﬁcult. Imagingmodal-
ities, such as magnetic resonance imaging (MRI), computerized tomog-
raphy (CT) and ultrasound (US) might not identify ovarian lesions
(Wang et al., 2001).
Selective venous catheterization has been recommended as an accu-
rate method for the diagnosis and localization of androgen-secreting
ovarian and adrenal tumors (Lobo, 1991; Cohen et al., 1993), especially
asmost ovarian androgen-producing tumors are small (Lobo, 1991) and
thus, difﬁcult to detect by imaging techniques (Sarfati et al., 2011).
However, diagnostic speciﬁcity of this technique is often disappointing
even in experienced hands (Sarfati et al., 2011). Moreover, in some
cases, pre-operative venous sampling was attempted but not achieved,
and thus venous samplingwas done intra-operatively during diagnostic
laparoscopy or explorative laparotomy (Kaltsas et al., 2003).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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hormone-producing ovarian tumors, we used a noninvasive hormonal
test. In this paper, we report on our experience using this noninvasive
hormonal test for the diagnosis of ovarian androgen and estrogen pro-
ducing tumors in postmenopausal women.
2. Material and methods
2.1. Case 1
A 58-year-old, Caucasian, healthy, menopausal, married, gravida, 2
para 2womanwas referred to our clinic for evaluation of progressive fa-
cial hirsutism, which had appeared one year earlier. The patient did not
take anymedications that had androgenic side-effects and had no famil-
ial history of virilization.
On examination, her weight was 63 kg and height 160 cm. Blood
pressure was normal. She had no striae or abnormal skin pigmentation.
No alopecia or acnewas noted. She presentedwithmild facial hirsutism.
General physical and gynecological examinations were normal. Pelvic
ultrasound revealed normal uterus, endometrial thickness was 3 mm,
right ovary measured 29 ∗ 33 mm and left ovary 20 ∗ 22 mm, without
evidence of tumor or cyst. There was no pelvic or abdominal mass.
Adrenal ultrasound was normal. Computerized tomography disclosed
bilateral adenoma of the adrenal glands.
Basal serum hormone levels are listed in Table 1.
A hormonal dynamic test was performed to determine the anatom-
ical location of the suspected hormone producing tumor (Table 1,
Fig. 1). The patient started daily oral dexamethasone (Rekah Pharma-
ceutical Industries Ltd., Holon, Israel) 1 mg per day. Seven days later,
hormonal blood sample was taken at 8:00 A.M. Immediately after, the
patient received one subcutaneous injection of GnRH antagonist (0.25
cetrorelix (Merck Serono S.A. Switzerland)). A day later, a second hor-
monal blood sample was performed at 8:00 A.M. Immediately after,
the patient received one subcutaneous injection of 250microgram cho-
riogonadotropin alpha (Merck Serono S.A. Switzerland). A day later (on
day 9), a third hormonal blood samplewas taken at 8:00 A.M, and dexa-
methasone was discontinued.
A ﬂow chart of the dynamic hormonal changes was drawn and the
anatomical location of the androgen overproduction was diagnosed
(Table 1). Based on the hormonal results indicating the presence of
ovarian androgen producing tumor, laparoscopic bilateral salpingo-
oophorectomy was performed. Histological evaluation revealed steroid
cell tumor in the right ovary. Left ovary and both fallopian tubes were
unremarkable. Preoperative and postoperative hormonal values are
listed in Table 1.
2.2. Case 2
A 58-year-old, Caucasian, menopausal, married, gravida 2, para 2
woman was referred to our clinic for evaluation of breast engorgementTable 1
Basal hormone values, hormone levels throughout the 9-day dynamic hormonal test and posto
Day 0 1–9 7
Medications and procedures Basal hormone values Dexa 1.0 mg daily Bloo
Hormone levels (normal range)
SHBG (18–144 nmol/L) 49 – 38
DHEAS (0.9–11.6 μmol/L) 2.71 – 1.25
Androstenedione (0.48–10.07 nmol/L) 5.21 – 1.6
Cortisol (nmol/L) (138–690) 314
17 OHP (0.6–5.2 nmol/L) 2.31 – 0.8
Total testosterone (nmol/L) (0.9–2.6) 8.2 – 9.2
SHBG (nmol/L) (18–44) 49
Free androgen index (0.2–12.0 nmol/L) 69 – 84
Estradiol (b70 pmol/L) 71 – 88
Dexa = dexamethasone; SHBG = sex hormone binding globulin; DHEAS = dehydroepiandroand an episode of postmenopausal bleeding. Two years ago, the patient
had coronary catheterization with insertion of coronary stents. The pa-
tient had hypertension andwas treatedwith bisoprolol fumarate 2.5mg
per day, rosuvastatin 20 mg per day, clopidogrel 75 mg per day and
valsartan hydrochloride 160/25 mg per day.
On vaginal ultrasound evaluation, the uterus had normal dimen-
sions, and endometrial thickness was 9.5 mm. A right ovarian cyst
34 ∗ 30 ∗ 30 mm with small hyperecogenic imprints was noted.
Doppler blood ﬂow was normal (RI = 0.34 and 0.4). The left ovary
was normal. Endometrial biopsy revealed endometrial hyperplasia
without atypia.
Adrenal ultrasound was normal. Carcinoma antigen 125 was within
normal limits (13.78 U/ml). Hormonal evaluation revealed high estradiol
levels, with no other hormonal abnormality (Table 2).
A hormonal dynamic test was then performed to determine the
anatomic location of the suspected hormone producing tumor (Table 2,
Fig. 2). The patient started daily oral dexamethasone (Rekah Pharmaceu-
tical Industries Ltd., Holon, Israel) 1mgper day. Sevendays later, hormon-
al blood sample was taken at 8:00 A.M. Immediately after, the patient
received one subcutaneous injection of GnRH— antagonist 0.25 cetrorelix
(Merck Serono S.A. Switzerland). A day later, a second hormonal blood
sample was performed at 8:00 A.M. Immediately after, the patient re-
ceived one subcutaneous injection of 75 μg follitropin alpha (Merck
Serono S.A. Switzerland). A day later (day 9), a third hormonal blood sam-
ple was taken at 8:00 A.M. and dexamethasone was discontinued.
A ﬂow chart of the dynamic hormonal changes was drawn and the
anatomical location of the estrogen overproduction was diagnosed
(Table 2).
Based on the hormonal results, indicating the presence of ovarian es-
trogen producing tumor, laparoscopic bilateral salpingo-oophorectomy
was performed. Histological evaluation revealed adult type granulosa
cell tumor in the right ovary. The left ovary and both fallopian tubes
were unremarkable. Preoperative and postoperative hormonal values
are listed in Table 2.3. Discussion
Detection of postmenopausal high androgen or estrogen production
requires identiﬁcation of the exact anatomic location of the hormone-
producing tissue, before performing a surgical procedure to remove
the pathological tissue. Although diagnostic imaging is recommended
(Taylor et al., 1986), sometimes it is very difﬁcult to detect and interpret
test results. Imagingmodalities, such asmagneticMRI, CT andUS,might
not identify ovarian lesions (Wang et al., 2001).
Selective venous catheterization has been recommended as an accu-
rate method for the diagnosis and localization of hormone-secreting
ovarian and adrenal tumors (Lobo, 1991; Cohen et al., 1993). However,
diagnostic speciﬁcity of this technique is often disappointing even in ex-
perienced hands (Kaltsas et al., 2003), and in some cases pre-operative
venous sampling was attempted but not achieved (Kaltsas et al., 2003).perative hormonal values (patient 1)
8 9 Post-operative








sterone sulfate; 17 OHP = 17 hydroxyprogesterone. Bold text indicates abnormal values.
Fig. 1. Algorithm of the 9-day dynamic LH hormonal test protocol (patient 1).
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Therefore, we thought to perform a noninvasive diagnostic procedure,
based on the physiological function of androgen or estrogen producing
cells.
The rationale for this procedure is that there is no need to lateralize
an ovarian tumor in postmenopausal patients (Sarfati et al., 2011). In
case of hormone-producing ovarian tumor in menopause, both ovaries
are removed.
The rationale for the hormonal diagnostic manipulation used for the
diagnostic procedure is based on the presence of luteinizing hormone
(LH) receptors on the theca cells. Theca cells are characterized by ste-
roidogenic activity in response to LH, speciﬁcally resulting in androgen
production (Hormone biosynthesis, 2011). Human chorionic gonadotro-
pin (hCG) stimulates testosterone production in both healthy (Hormone
biosynthesis, 2011) and hyperandrogenic women (Rosenﬁeld et al.,
1990).
It has been shown that gonadotropin releasinghormone (GnRH)-ag-
onist suppresses LH dependent ovarian steroidogenesis and does not
appear to affect adrenal androgen secretion (Lobo, 1991). Moreover,
GnRH-agonist treatment may suppress testosterone to levels found in
oophorectomized women (Chang et al., 1983).
We used oral steroids to induce adrenal hormonal depression.
Decrease in androgens or estradiolmight indicate the presence of an ad-
renal tumor due to elimination of direct adrenal production of andro-
gens and/or subsequent conversion to estradiol by aromatase.
Once adrenal depression was achieved, we induced ovarian andro-
gen hormonal depression by using GnRH-antagonist. Decrease in an-
drogen levels may indicate potential ovarian androgen producing
tumor, as it has been demonstrated that GnRH-agonist suppression of
gonadotropins lowered serum testosterone levels in virilized women
having basal increased serum testosterone and gonadotropin levelsTable 2
Basal hormone values, hormone levels during the 9-day dynamic hormonal test and postopera
Day 0 1–9 7
Medications and procedures Basal hormone values Dexa 1.0 mg daily Blo
Hormone levels (normal range)
SHBG (18–144 nmol/L) – 24
DHEAS (0.9–11.6 μmol/L) 1.37 – 0.5
Androstenedione (0.48–10.07 nmol/L) 3.73 – 0.5
Cortisol (138–690 nmol/L) 475
17 OHP (0.6–5.2 nmol/L) 0.51 – 0.4
Total testosterone (0.9–2.6 nmol/L) 0.9 – 1.2
Free androgen index (0.2–12.0 nmol/L) – – 1.4
Estradiol (b70 pmol/L) 431 – 158
Dexa = dexamethasone; SHBG = sex hormone binding globulin; DHEAS = dehydroepiandro(Lamberts et al., 1982). Therefore, it was suggested that androgen secre-
tion by ovarian virilizing tumors, as well as hyperthecosis, is not autono-
mous, but apparently depends on continuous gonadotropin stimulation
and thus, is gonadotropin dependent (Lamberts et al., 1982). Further-
more, in an in vitro study of androblastoma, Lamberts et al. demonstrated
a suppressive effect of GnRH-agonist on androgen secretion by a direct
effect on the ovarian tumor (Lamberts et al., 1982).
In a previous study, we demonstrated that three weeks after a
subcutaneous injection of 3.75 mg GnRH-agonist, LH and testosterone
levels decreased dramatically in a postmenopausal patient with ovarian
Sertoli–Leydig cell tumor (Sarfati et al., 2011). Moreover, GnRH-agonist
has been shown to suppress elevated androgen levels in patients
with Leydig cell ovarian tumor (Kennedy et al., 1987), hyperthecosis
(Lamberts et al., 1982), granulosa cell ovarian tumor (Martikainen
et al., 1989), hilus cell ovarian tumor (Rosenﬁeld et al., 1990), Sertoli–
Leydig ovarian tumor and steroid-cell ovarian tumor (Brewer and
Douglas, 1998).
Using GnRH-antagonist induces immediate ovarian hormonal
depression, similar to the depressive, but delayed action of GnRH-
agonist. Subsequent administration of LH may irritate the androgen
tumor cells and consequently provoke higher androgen levels. We
have previously shown during selective venous catheterization, that
15 min after administration of intravenous injection of hCG, testoster-
one and androstenedione levels increased 6.5- to 7-fold, while there
were only mild elevations of basal levels of these two hormones in a
postmenopausal patient with ovarian Leydig cell tumor (Cohen et al.,
1993) and in a postmenopausal patient with ovarian hyperthecosis
(Sarfati et al., 2011). In the ﬁrst case, androgen levels decreased follow-
ing GnRH-antagonist injection and subsequently increased signiﬁcantly
following LH injection. Moreover, histological evaluation revealed
steroid cell tumor in the ovary.tive hormonal values (patient 2)
8 9 Post-operative
od test, GnRH-antagonist 250 μg Blood test, FSH 75 IU Blood test
25 23
4 0.54 0.54 1.21
8 0.5 0.58 3.37
6 0.46 0.46 0.57
2 1.22 1.22 0.9
1.4 1.4 –
73 118 b70
sterone sulfate; 17 OHP = 17 hydroxyprogesterone. Bold text indicates abnormal values.
Fig. 2. Algorithm of the 9-day dynamic FSH hormonal test protocol (patient 2).
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same hormonal test. However, instead of subsequent administration
of LH, we injected follicular-stimulating hormone (FSH), as it may irri-
tate the estrogen producing cells and consequently provoke higher es-
trogen levels. It is well known that FSH receptors are present on the
granulosa cells and FSH induces aromatization of androgens to estro-
gens in the granulosa cells (Hormone biosynthesis, 2011).
In the second case, estradiol level decreased following GnRH-
antagonist injection and subsequently, increased signiﬁcantly after
FSH injection. Moreover, histological evaluation revealed granulosa
cell tumor in the ovary. Neither patient experienced any side effects
during the hormonal study.
To conclude, to the best of our knowledge, these are the ﬁrst
cases showing the efﬁcacy of a noninvasive hormonal test for de-
tecting postmenopausal hormone-producing ovarian tumors. The
test is simple, safe and the patients did not experience side effects.
The proposed hormonal test can be considered in postmenopausal
women suspected of having androgen and/or estrogen producing
tumors, especially in cases with no adnexal pathology on imaging
studies/pelvic exam, as well as in cases with abnormalities present
on imaging studies that are unlikely to prompt immediate surgical
intervention. Due to the small number of patients, our results should
be conﬁrmed in larger studies.
Disclosure statement
The authors have nothing to disclose.
References
Brewer, C.A., Douglas, S., 1998. Encouraging response of an advanced steroid-cell tumor to
GnRH agonist therapy. Obstet. Gynecol. 92, 661–663.Chang, R.J., Laufer, L.R., Meldrum, D.R., DeFazio, J., Lu, J.K., Vale, W.W., Rivier, J.E., Juded,
H.L., 1983. Steroid secretion in polycystic ovarian disease after ovarian suppression
by a long-acting gonadotropin-releasing hormone agonist. J. Clin. Endocrinol.
Metab. 56, 897.
Cohen, I., Shapira, M., Cuperman, S., Goldberger, S., Siegal, A., Altaras, M., Beyth, Y., 1993.
Direct in-vivo detection of atypical hormonal expression of a Sertoli-Leydig cell tu-
mour following stimulation with human chorionic gonadotrophin. Clin. Endocrinol.
39, 491–495.
Geetha, P., Nair, M.K., 2010. Granulosa cell tumors of the ovary. Aust. N. Z. Obstet. Gynecol.
50, 216–220.
Hormone biosynthesis, 2011. Metabolism and mechanism of action. In: Fritz, M.A.,
Speroff, L. (Eds.), Clinical Gynecologic Endocrinology and Infertility, 8th ed. Lippincott
Williams & Wilkins, Philadelphia, pp. 41–42.
Kaltsas, G.A., Mukherjee, J.J., Kola, B., Isidori, A.M., Hanson, J.A., Dacie, J.E., Reznek, R.,
Monson, J.P., Grossman, A.B., 2003. Is ovarian adrenal venous catheterization and
sampling helpful in the investigation of hyperandrogenic women? Clin. Endocrinol.
59, 34–43.
Kennedy, L., Traub, A., Atkinson, A.B., 1987. Short term administration of gonadotrophin
releasing hormone analog to a patient with a testosterone secreting ovarian tumor.
J. Clin. Endocrinol. Metab. 64, 1320–1322.
Lamberts, S.W.J., Timmers, J.M., Oosterom, R., Verleun, T., Rommerts, F.G., 1982. deJong
FH. Testosterone secretion by cultured arrhenoblastoma cells: suppression by lutein-
izing hormone releasing hormone agonist. J. Clin. Endocrinol. Metab. 54, 450–454.
Lobo, R.A., 1991. Ovarian hyperandrogenism and androgen-producing tumors.
Endocrinol. Metab. Clin. N. Am. 20, 773–805.
Mancaux, A., Gardel Chambenoit, E., Gagner, O., Nasreddine, A., Gondry, J., Merviel, P.,
2013. Granulosa cell tumor: difﬁculty of diagnosis and contribution of imaging.
Gynecol. Obstet. Fertil. 41, 439–445.
Martikainen, H., Penttinen, J., Huhtaniemi, I., Kauppila, A., 1989. Gonadotropin-releasing
hormone agonist analog therapy effective in ovarian granulose cell malignancy.
Gynecol. Oncol. 35, 406–408.
Rosenﬁeld, R.L., Barnes, R.B., Cara, J.F., Lucky, A.W., 1990. Dysregulation of cytochrome
P450c17α as the cause of polycystic ovarian syndrome. Fertil. Steril. 53, 785.
Sarfati, J., Bachelot, A., Coussieu, C., Meduri, G., Tourine, P., 2011. Impact of clinical, hor-
monal, radiological and immunohistochemical studies on the diagnosis of postmeno-
pausal hyperandrogenism. Eur. J. Endocrinol. 165, 779–788.
Taylor, L., Ayers, J.W., Gross, M.D., Peterson, E.P., Menon, K.M., 1986. Diagnostic consider-
ations of virilization: iodomethyl-norcholesterol scanning in the localization of an-
drogen secreting tumors. Fertil. Steril. 46, 1005–1010.
Wang, P.-H., Chao, H.-T., Liu, R.-S., Cho, Y.-H., Ng, H.-T., Yoan, C.-C., 2001. Diagnosis and
localization of testosterone-producing ovarian tumors: imaging or biochemical
evaluation. Gynecol. Oncol. 83, 596–598.
